Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06611033 · ClinicalTrials.gov registry record · Phase 1
A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 65
- Enrollment target
NCT06611033: Completed Phase 1 study, sponsored by Merck Sharp & Dohme.
NCT06611033 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 65 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06611033, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 65 participants
- Enrollment target
Study Summary
The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
Primary Outcome
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The number of participants with a solicited injection-site AE will be reported.
Interventions
- BIOLOGICAL Saline
- BIOLOGICAL PREVNAR 20™
- BIOLOGICAL V118C
- BIOLOGICAL V118
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2026-01-09 |
| Phase | Phase 1 |
What the finished NCT06611033 record still lists
NCT06611033 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 4 interventions - of which Saline is the first listed.
NCT06611033 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06611033 about?
NCT06611033 is a clinical study titled "A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)". The goal of this study is to learn how safe V118 Formulation C is in Healthy Adults and how well people tolerate it.
What is the current status of trial NCT06611033?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 65 participants. The study started on 2024-09-25. Estimated completion is 2026-01-09.
What interventions are being tested in trial NCT06611033?
The interventions under investigation include: Saline (BIOLOGICAL), PREVNAR 20™ (BIOLOGICAL), V118C (BIOLOGICAL), V118 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06611033?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06611033's enrollment target sits among peer trials
65 798th of 2000 higher than 1,193 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI